Structure-activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors

被引:113
作者
Maccari, R
Ottanà, R
Curinga, C
Vigorita, MG
Rakowitz, D
Steindl, T
Langer, T
机构
[1] Univ Messina, Fac Farm, Dipartimento Farmacochim, I-98168 Messina, Italy
[2] Univ Innsbruck, Dept Pharmaceut Chem, Inst Pharm, A-6020 Innsbruck, Austria
关键词
2,4-thiazolidinediones; aldose reductase; diabetes mellitus; molecular modelling;
D O I
10.1016/j.bmc.2005.02.026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The structure-activity relationships (SARs) of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors (ARIs) were extended by varying the substitution pattern on the 5-arylidene moiety and on N-3. In particular, the introduction of an additional aromatic ring or an H-bond donor group on the 5-benzylidene ring enhanced ALR2 inhibitory potency. Moreover, the presence of a carboxylic anionic chain on N-3 was shown to be an important, although not essential, structural requisite to produce high levels of ALR2 inhibition. The length of this carboxylic chain was critical and acetic acids 4 were the most effective inhibitors among the tested derivatives. Molecular docking simulations into the ALR2 active site accorded with the in vitro inhibition data. They allowed the rationalization of the observed SARs and provided a pharmacophoric model for this class of ARIs. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2809 / 2823
页数:15
相关论文
共 34 条
[1]  
*ACC INC, 2003, CER 2 REL 4 9
[2]  
*ACC INC, 2003, CAT REL 4 7
[3]   Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones [J].
Bruno, G ;
Costantino, L ;
Curinga, C ;
Maccari, R ;
Monforte, F ;
Nicolò, F ;
Ottanà, R ;
Vigorita, MG .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (04) :1077-1084
[4]   The structure of human aldose reductase bound to the inhibitor IDD384 [J].
Calderone, V ;
Chevrier, B ;
Van Zandt, M ;
Lamour, V ;
Howard, E ;
Poterszman, A ;
Barth, P ;
Mitschler, A ;
Lu, JH ;
Dvornik, DM ;
Klebe, G ;
Kraemer, O ;
Moorman, AR ;
Moras, D ;
Podjarny, A .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2000, 56 :536-540
[5]  
Castaner J., 1987, DRUGS FUTURE, V12, P336
[6]  
CHOU TC, 1996, CALCUSYN SOFTWARE VE
[7]   Pharmacological approaches to the treatment of diabetic complications [J].
Costantino, L ;
Rastelli, G ;
Gamberini, MC ;
Barlocco, D .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (08) :1245-1262
[8]  
Costantino L, 1999, MED RES REV, V19, P3, DOI 10.1002/(SICI)1098-1128(199901)19:1<3::AID-MED2>3.0.CO
[9]  
2-7
[10]   New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications [J].
Costantino, L ;
Rastelli, G ;
Cignarella, G ;
Vianello, P ;
Barlocco, D .
EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (08) :843-858